XLO
Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.13
+1.00%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.82
- Revenue estimate
- $4.8M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.33
- EPS estimate
- -$0.59
- Revenue actual
- $18.7M
- Revenue estimate
- $12.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +26.4%
- Revenue beats (12Q)
- 4
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.59 | -$0.33 | Beat 44.07% | $18.7M |
| May 12, 2026 | -$0.66 | -$0.58 | Beat 12.12% | $12.7M |
| Mar 23, 2026 | -$1.68 | -$0.85 | Beat 49.40% | $13.7M |
| Nov 13, 2025 | -$0.03 | -$0.03 | In line | $19.1M |
| Aug 14, 2025 | -$0.08 | -$0.16 | Miss -100.00% | $8.1M |
| May 8, 2025 | $0.10 | -$0.18 | Miss -280.00% | $2.9M |
| Mar 11, 2025 | -$0.22 | -$0.20 | Beat 9.09% | $1.7M |
| Nov 7, 2024 | -$0.25 | -$0.22 | Beat 12.00% | $2.3M |
| Aug 8, 2024 | -$0.23 | -$0.24 | Miss -4.35% | $2.4M |
| Apr 1, 2024 | -$0.62 | -$0.64 | Miss -3.23% | $2.9M |
| Nov 9, 2023 | -$0.76 | -$0.61 | Beat 19.74% | — |
| Nov 9, 2022 | -$0.89 | -$0.72 | Beat 19.10% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026